Additional approaches to the one we describe here, have focused on developing therapeutics that increase the expression of NKG2D on NK cells (27, 107, 108) or enhance the expression levels of NKG2D ligands, as has been tested for Ewing sarcoma cell lines (109, 110). This evidence concerns the gene KLRK1 and Ewing sarcoma.